TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05052983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemolizumab
Description: Participants received either 1 \[30 milligram (mg)\] or 2 (2\*30 mg) subcutaneous (SC) injection(s) of nemolizumab every 4 weeks (Q4W) for a period of 24 weeks (with last injection at Week 20). Participants received the same dosage (1 or 2 SC injections) as received in the lead-in LTE study RD.06.SPR.202699, as assigned by interactive response technology (IRT).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received either 1 (30 mg) or 2 (2\*30 mg) SC injection(s) of placebo every 4 weeks for a period of 24 weeks (with last injection at Week 20). Participants received the same dosage (1 or 2 SC injections) as received in the lead-in LTE study RD.06.SPR.202699, as assigned by IRT.
Study: NCT06713603

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAMI Coach
Description: The investigators address the problems of intrinsic motivation, Evidence Based Practice (EBP) education, and referral tailoring using a digital-coaching intervention that 1) promotes readiness to change, 2) educates and builds confidence about EBP's, and 3) creates a tailored quit plan sensitive to social obstacles and needs.
Study: NCT06713395

Intervention type: OTHER
Group type: OTHER
Intervention: The control group received standard postoperative care
Description: standard postoperative care

Intervention type: OTHER
Group type: OTHER
Intervention: PERMA
Description: 1. Establishment of the Integrated Psychological Intervention Team:~   The team consisted of 2 primary nurses, 4 specialist nurses, 1 psychologist, 2 physicians at the attending level or higher, and 2 researchers.~   Team Responsibilities: The primary and specialist nurses were responsible for implementing the intervention protocol. The physicians handled any adverse reactions experienced by the patients. The researchers were in charge of developing the intervention protocol and collecting data. All team members were required to undergo specialized training from the psychologist and pass an assessment before initiating the intervention.~2. Protocol Development:~   The intervention protocol, including specific content, team responsibilities, implementation process, and responses to adverse events, was carefully developed in written form by the researchers. The protocol was discussed and approved by all team members before implementation.~3. Protocol Implementation:~Emotional Support Intervention:
Study: NCT06711796

Intervention type: DEVICE
Intervention: emg measurement in adductor pollucis
Description: EMG measurement from adductor pollucis and dorsal interosseus muscles in supination and pronation using increasing stimulation current
Study: NCT06712979

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adapted Lee Silverman Method
Description: Exercise protocol with 6 steps that the voice professionals adapted from Lee Silverman Method

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lung volume recruitment technique - LVRT
Description: The adapted Lee Silverman Method will have a addiction of LVRT technique. Lung inflation begins, reaching an optimal inspiratory peak of 30 cmH2O. From this point, the sound /HA/ begins to be emitted until the most comfortable low sound, where the emission should be maintained for as long as possible, making sure that this time is not less than 12 seconds, trying to emit a high and comfortable vocal intensity. When performing the emissions, the mouth should be kept wide open with the tongue, jaw and neck relaxed, repeating 5 emissions in 3 series. Between series, the participant will be instructed to drink 50 ml of water exactly as in the previous emissions.
Study: NCT06711263

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mouthwash Product
Description: * In the Initial Visit-Baseline, and subsequent visits, participants will be called in the morning. Morning hours will be chosen for examination, as it will reduce the risk of bias and also help in quantifying results. plaque and gingival scores will be recorded and the First herbal mouthwashes will be given, participants will also be provided new tooth-brushes (Oral B-soft).~* They will be asked to follow their routine oral hygiene habits. They will be asked to come back after 2 weeks for plaque and gingival bleeding scores recording for the second visit and again after 2weeks post the second visit for the third and final visit to record their plaque and gingival bleeding scores.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mouthwash Product
Description: * In the Initial Visit-Baseline, and subsequent visits, participants will be called in the morning. Morning hours will be chosen for examination, as it will reduce the risk of bias and also help in quantifying results. plaque and gingival scores will be recorded and the First herbal mouthwashes will be given, participants will also be provided new tooth-brushes (Oral B-soft).~* They will be asked to follow their routine oral hygiene habits. They will be asked to come back after 2 weeks for plaque and gingival bleeding scores recording for the second visit and again after 2weeks post the second visit for the third and final visit to record their plaque and gingival bleeding scores.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mouthwash Product
Description: * In the Initial Visit-Baseline, and subsequent visits, participants will be called in the morning. Morning hours will be chosen for examination, as it will reduce the risk of bias and also help in quantifying results. plaque and gingival scores will be recorded and the First herbal mouthwashes will be given, participants will also be provided new tooth-brushes (Oral B-soft).~* They will be asked to follow their routine oral hygiene habits. They will be asked to come back after 2 weeks for plaque and gingival bleeding scores recording for the second visit and again after 2weeks post the second visit for the third and final visit to record their plaque and gingival bleeding scores.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mouthwash Product
Description: * In the Initial Visit-Baseline, and subsequent visits, participants will be called in the morning. Morning hours will be chosen for examination, as it will reduce the risk of bias and also help in quantifying results. plaque and gingival scores will be recorded and the First herbal mouthwashes will be given, participants will also be provided new tooth-brushes (Oral B-soft).~* They will be asked to follow their routine oral hygiene habits. They will be asked to come back after 2 weeks for plaque and gingival bleeding scores recording for the second visit and again after 2weeks post the second visit for the third and final visit to record their plaque and gingival bleeding scores.
Study: NCT05866016

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Skill birth attendant training
Description: It is an intervention targeted to enhance the competencies of Maternal Neonatal Health (MNH) service providers (skilled birth attendants) in Nepal. It is a capacity-building intervention that is expected to contribute to reducing maternal and neonatal morbidities and mortalities by improving the midwifery competencies (knowledge, attitudes, and skills) of MNH service providers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skill birth attendant training
Description: It is an intervention targeted to enhance the competencies of Maternal Neonatal Health (MNH) service providers (skilled birth attendants) in Nepal. It is a capacity-building intervention that is expected to contribute to reducing maternal and neonatal morbidities and mortalities by improving the midwifery competencies (knowledge, attitudes, and skills) of MNH service providers.
Study: NCT06253663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KTE-X19
Description: A single infusion of chimeric antigen receptor (CAR) T cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KTE-X19
Description: A single infusion of chimeric antigen receptor (CAR) T cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously
Study: NCT06507657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: empagliflozin
Description: intake of a 10mg empagliflozin oral tablet~At visit 1, after randomization, participants will be provided with bottles containing enough study pills for 3 months duration at 1 tablet daily. Participants will start the study drug on the morning following Visit 1. At the 3 month follow up visit, participants will be provided with enough study pills to complete the remaining 6 months of the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: intake a placebo oral tablet~At visit 1, after randomization, participants will be provided with bottles containing enough study pills for 3 months duration at 1 tablet daily. Participants will start the study drug on the morning following Visit 1. At the 3 month follow up visit, participants will be provided with enough study pills to complete the remaining 6 months of the study.
Study: NCT06025734

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Tibial Nerve Stimulation (TTNS) treatment
Description: Spina Bifida pediatric patients with neurogenic bladder will be in Transcutaneous Tibial Nerve Stimulation (TTNS) treatment. Patient will complete 6 weeks of 30 minute treatment sessions (these can be done at home after the first teaching session)
Study: NCT05479045

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 Peptide vaccine
Description: 300 mcg of NY-ESO-1 peptide, 100 micrograms (mcg) granulocyte-macrophage colony-stimulating factor (GM-CSF) and 1 milliliter (mL) of Montanide ISA-51 adjuvant. The first two doses will be administered subcutaneously in a 2 week interval and thereafter, remaining three doses will be administered every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab-tpzi
Description: 240 milligrams (mg), intravenously, every 3 weeks starting with the second dose of NY-ESO-1 Peptide vaccine
Study: NCT05763004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IOS-1002
Description: monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IOS-1002 + KEYTRUDA® (pembrolizumab)
Description: combination therapy
Study: NCT05117515

Intervention type: DEVICE
Intervention: Vascular reconstruction
Description: Vascular reconstructions in the carotid, profunda, femoral and iliac arteries
Study: NCT06128187

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Participants will receive treatment 5 days a week, 45 minutes a day for 6 weeks. After the traditional rehabilitation program, 30 minutes of virtual reality training will be given.
Study: NCT05681741

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: current versus high pump flow
Description: during each phase of randomized pump flow, arterial pressure will be increased from 40 to 90 mmHg with vasodilators and/or vasoconstrictors
Study: NCT06492577

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation protocol
Description: In the initial phase (days 1-7), aerobic exercise sessions will be 20-30 minutes, strength training will include 1-2 sets at 50% of 1RM, and breathing exercises will last 10 minutes daily. In the progressive phase (days 8-14), aerobic exercise sessions will increase to 30-40 minutes, strength training to 2-3 sets at 60% of 1RM, and breathing exercises to 10-15 minutes daily. In the advanced phase (days 15-21), aerobic exercise sessions will be 40-45 minutes, strength training will be 2-3 sets at 70% of 1RM, and breathing exercises will continue for 10-15 minutes daily.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary rehabilitation protocol
Description: In the initial phase (days 1-7), aerobic exercise sessions will be 20-30 minutes, strength training will include 1-2 sets at 50% of 1RM, and breathing exercises will last 10 minutes daily. In the progressive phase (days 8-14), aerobic exercise sessions will increase to 30-40 minutes, strength training to 2-3 sets at 60% of 1RM, and breathing exercises to 10-15 minutes daily. In the advanced phase (days 15-21), aerobic exercise sessions will be 40-45 minutes, strength training will be 2-3 sets at 70% of 1RM, and breathing exercises will continue for 10-15 minutes daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation protocol
Description: Participants in this arm will undergo a 21-day progressive muscle relaxation (PMR) program aimed at reducing anxiety and improving sleep quality in patients with long-term COVID-19 symptoms. Each daily session lasts 20 minutes and involves systematic muscle tensing and relaxation, starting from the feet and progressing to the head, combined with slow, deep breathing. During the initial phase (days 1-7), the focus is on introducing PMR techniques and targeting different muscle groups. In the progressive phase (days 8-14), full-body PMR sessions enhance relaxation and breathing techniques. The advanced phase (days 15-21) maximizes relaxation and incorporates visualization techniques.
Study: NCT05629598

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin injection
Description: The dose of PEG-EPO (CHO cells) is converted according to the average weekly dose of short-acting EPO before randomization (4 weeks before randomization) multiplied by the corresponding conversion coefficient (low conversion coefficient is 0.004, High conversion coefficient is 0.008).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin injection
Description: The dose of PEG-EPO (CHO cells) is converted according to the average weekly dose of short-acting EPO before randomization (4 weeks before randomization) multiplied by the corresponding conversion coefficient (low conversion coefficient is 0.004, High conversion coefficient is 0.008).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin injection
Description: The dose of PEG-EPO (CHO cells) is converted according to the average weekly dose of short-acting EPO before randomization (4 weeks before randomization) multiplied by the corresponding conversion coefficient (low conversion coefficient is 0.004, High conversion coefficient is 0.008).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin injection
Description: The dose of PEG-EPO (CHO cells) is converted according to the average weekly dose of short-acting EPO before randomization (4 weeks before randomization) multiplied by the corresponding conversion coefficient (low conversion coefficient is 0.004, High conversion coefficient is 0.008).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Human erythropoietin injection
Description: Refer to the product instructions
Study: NCT06026189

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: urine-first strategy
Description: Only patients with an abnormal urine test result undergo a diagnostic workup, i.e. cystoscopy and upper-tract imaging.
Study: NCT05394402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0410 Injection
Description: SHR0410 Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0410 Injection
Description: SHR0410 Injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for SHR0410 Injection
Description: SHR0410 Injection blank preparation
Study: NCT05512260

Intervention type: DEVICE
Group type: OTHER
Intervention: Individual decision aid (iDA)
Description: A web-based iDA (accessible online with various content), will be developed towards individuals approached to cancer screening, although public and accessible to all who are interested in cancer and screening. DAs in screening usually include information on the disease, screening, screening tests, benefits and harms and some value clarification exercise (e.g., interactive questions) aiming at shedding light on the individual´s values and preferences, knowledge and lifestyle.
Study: NCT06128187

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Study Group
Description: Participants will receive treatment 5 days a week, 45 minutes a day for 6 weeks. After the traditional rehabilitation program, 30 minutes of dual-task training will be given
Study: NCT04861740

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autism ALERT
Description: Autism Access Link for Early Referral and Treatment \[ALERT\], the intervention proposed in this application, is a novel state-wide referral and case management platform that PCPs can activate to ensure that a child with suspected ASD receives all necessary ASD diagnosis and treatment resources in a single referral, radically simplifying a complex diagnostic and treatment process.
Study: NCT04265053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganirelix Acetate
Description: Gonadotropin-Releasing Hormone (GnRH) antagonist ganirelix acetate as a model to isolate estrogen and testosterone effects on the cerebrovascular system. Participants receive daily injections of ganirelix for 12-14 days for Aim 3 studies only. This will be overseen by clinical endocrinologists.~Both males and females receive this treatment in Aim 3.
Study: NCT05025449

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Focused Assessment with Sonography for Trauma (FAST)
Description: The Focused Assessment with Sonography for Trauma (FAST) exam is widely used and accepted as part of Advanced Trauma Life Support (ATLS) protocol. After consent, a baseline FAST exam will be performed and documented. This FAST will be distinct from the initial ATLS resuscitation FAST in order to avoid any interference in the trauma evaluation. The investigator will use a phased array or curvilinear transducer to record video of their baseline FAST exam.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bubble-Enhanced FAST (BEFAST)
Description: Following the FAST exam and using the same machine, a BEFAST exam will be performed using a low mechanical index setting in contrast-specific imaging mode. A 2.4 mL IV dose of Lumason will be injected into the subject's IV, followed by saline flush. The contrast will be injected once for the right side of the body, and once for the left side of the body looking for disruptions in the normal enhancement pattern and evidence of active bleeding. To examine the right side of the body: the liver will be imaged first in arterial phase, followed by the right kidney, before returning to image the liver in venous phase. To examine the left side of the body: the pancreas will be imaged first, followed by the kidney and the spleen. The investigator will note evidence of solid organ injury, free fluid, or active extravasation on both sides of the body; lacerations will be graded by the American Association for the Surgery of Trauma (AAST) criteria.
Study: NCT05681741

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: current versus high pump flow
Description: during each phase of randomized pump flow, arterial pressure will be increased from 40 to 90 mmHg with vasodilators and/or vasoconstrictors
Study: NCT04861740

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Screening Intervention
Description: Autism screening intervention only.
Study: NCT04265053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganirelix Acetate
Description: Gonadotropin-Releasing Hormone (GnRH) antagonist ganirelix acetate as a model to isolate estrogen and testosterone effects on the cerebrovascular system. Participants receive daily injections of ganirelix for 12-14 days for Aim 3 studies only. This will be overseen by clinical endocrinologists.~Both males and females receive this treatment in Aim 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganirelix Acetate
Description: Gonadotropin-Releasing Hormone (GnRH) antagonist ganirelix acetate as a model to isolate estrogen and testosterone effects on the cerebrovascular system. Participants receive daily injections of ganirelix for 12-14 days for Aim 3 studies only. This will be overseen by clinical endocrinologists.~Both males and females receive this treatment in Aim 3.
Study: NCT04903483

Intervention type: OTHER
Group type: OTHER
Intervention: bispectral index monitoring
Description: intraoperative single-channel electroencephalography monitoring of the depth of anesthesia

Intervention type: OTHER
Group type: OTHER
Intervention: bispectral index monitoring
Description: intraoperative single-channel electroencephalography monitoring of the depth of anesthesia
Study: NCT05623280

Intervention type: DRUG
Intervention: Indocyanine green
Description: Injection around the areola with 2-4 points Indocyanine green with 2ml of 1.25mg/mL
Study: NCT06306859

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Using m-health for monitoring and education provision
Description: The intervention group will be given access to m-health. The m-health aims to monitor patient's status i.e blood pressure, heart rate, fluid intake, dietary intake. In addition, there will be education provided through the m-health. The education will be on fluid and diet adherence

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: The comparator group will be given standard and routine care
Study: NCT06473519

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVpreF MDV
Description: RSVpreF with 2-PE formulated in an MDV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVpreF SDV
Description: RSVpreF without 2-PE formulated in an SDV
Study: NCT05582616

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: See treatment arm description

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation
Description: See sham comparator arm description
Study: NCT06631781

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GOLD-Cog+
Description: 6 weeks of combined cognitive intervention (GOLD-Cog+),which includes participation in 9, one hour long Cognitive-Orientation to Occupational Performance(CO-OP)-based group sessions and 24 individual and independent 30-minute computerized cognitive training (CCT) program using the Effectivate platform (Israeli-based CCT developed for older adults. Available in both Hebrew and English).